June Off to a Poor ...
Health Care: Drugs
AMAG Pharmaceuticals Inc. (AMAG: NASDAQ)
$13.58 -0.45 | -3.21%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -77.07M | -81.15M | -93.35M | -71.65M |
| Operating Gains/Losses | 193.00K | -408.00K | -942.00K | 3.02M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -134.00K | 21.12M | -26.94M | -185.00K |
| (Increase) Decrease in Inventories | 1.51M | -6.68M | -9.06M | 288.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 9.68M | 0.00 |
| (Decrease) Increase In Payables | 1.70M | 2.74M | 13.22M | 6.60M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | -294.00K | -68.00K | 0.00 |
| (Increase) Decrease In Other Working Capital | -6.70M | 46.70M | 0.00 | 3.05M |
| Other Non-Cash Items | 8.87M | 14.83M | 15.11M | 6.47M |
| Net Cash From Continuing Operations | -63.80M | -1.53M | -90.72M | -52.34M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -63.80M | -1.53M | -90.72M | -52.34M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -507.00K | -1.22M | -2.84M | -8.18M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 61.00K | -426.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 14.00M | -103.74M | 71.46M | 87.15M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 629.00K | 167.79M | 5.20M | 1.16M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 629.00K | 167.79M | 5.20M | 1.16M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -49.17M | 62.52M | -14.06M | 35.97M |
Portfolios with AMAG
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- UserPelican Watch
- UserPART 1 JPMorgan 28th Annual...
- UserPART 1 JPMorgan 27th Annual...
- Userileana
- UserShawen Portfolio 1
- Userfiallo Portfolio 1
- UserTSimao Portfolio 1
- Usersggrimsley
Latest AMAG Headlines from TheStreet
- 8 Stocks Rising on Huge Volume 04.20.12 | 01:04 pm
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Insiders Trading AMAG, CLWR, GTXI 03.06.12 | 10:03 am
- More Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- The Next Big Thing In Biotech: 2012 Outlook
01.06.12 | 05:01 am - 5 Stocks Poised for Breakouts 11.07.11 | 09:11 am
- Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
Press Releases for AMAG
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Investor Conferences - Business Wire 05.29.12 | 05:05 pm
- AMAG Pharmaceuticals Appoints William Heiden As President And Chief Executive Officer - Business Wire 05.09.12 | 04:05 pm
- AMAG Pharmaceuticals, Inc. To Host Conference Call On May 1, 2012 At 4:30 P.m. ET To Discuss Financial Results For The Quarter Ended March 31, 2012 - Business Wire 04.24.12 | 04:04 pm
- AMAG Pharmaceuticals Announces A Positive CHMP Opinion For The Approval Of Ferumoxytol In Europe For The Treatment Of Iron Deficiency Anemia In Adult Patients With Chronic Kidney Disease - Business Wire 04.20.12 | 09:04 am
- AMAG Pharmaceuticals Announces Preliminary Results From Its Phase III Study Evaluating Feraheme Compared To IV Iron Sucrose In Patients With Iron Deficiency Anemia - Business Wire 03.07.12 | 04:03 pm
- AMAG Pharmaceuticals, Inc. To Host Conference Call On March 7, 2012 At 4:30 P.m. ET To Discuss Feraheme Clinical Trial Results - Business Wire 03.06.12 | 04:03 pm
- AMAG Announces Fourth Quarter And Year End 2011 Financial Results - Business Wire 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals, Inc. To Present At The 24th Annual ROTH Conference - Business Wire 03.02.12 | 04:03 pm
- AMAG Pharmaceuticals, Inc. To Host Conference Call On March 5, 2012 At 4:30 P.m. ET To Discuss Financial Results For The Fourth Quarter And Year Ended 2011 - Business Wire 02.23.12 | 04:02 pm
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Investor Conferences - Business Wire 02.13.12 | 04:02 pm
Partner Headlines for AMAG
- AMAG Beats Riding on Feraheme Sales - Analyst Blog - Zacks 05.02.12 | 10:05 am
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- Israel Englander's Stock Picks With Insider Purchases - Seeking Alpha 01.18.12 | 09:01 am
- 17 Breakout Stocks Boosted By Insiders - Seeking Alpha 12.30.11 | 04:12 pm
- McNicoll Lewis & Vlak Raises PT on AMAG Pharmaceuticals to $23 - Benzinga 12.12.11 | 01:12 pm
- Mid-Day Update: Stocks Pare Some Early Losses; Unemployment Claims Lift Sentiment - NASDAQ 11.17.11 | 05:11 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.26.11 | 09:10 am
- Stocks Rally on European Debt Summit Optimism; December Crude Surges Over 2% - NASDAQ 10.21.11 | 04:10 pm
